Biologics & Biosimilars · Infectious Disease Therapeutics
Invivyd: Funding & valuation
Invivyd: 3 money records, each linked to its source.
Data updated Nov 20, 2026 · Back to the company report
Financials
Revenue of $53.4M in 2025. +110.5% on the year before. Net income −$52.5M.
$53.4MRevenue2025 · +110.5%
−$52.5MNet income2025 · +69.1%
Revenue by yearas filed, with the net income
Sources: SEC
Money
Invivyd: 3 money records, each linked to its source.
$155kCapital expenditureFY2025
From its filingssec.gov ↗
| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Shares bought back | $1k | – | – |
| Capital expenditure | $615k | $140k | $155k |
| Stock-based compensation | $18.7M | $19.8M | $11.6M |
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
